Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms

被引：0
作者：
Johnson, Toby
Xu, Chun-fang
Choueiri, Toni K.
Deen, Keith C.
Xue, Zhengyu
Bartlett-Pandite, Arundathy N.
Carpenter, Christopher
Motzer, Robert John
机构：
[1] GlaxoSmithKline, Uxbridge, Middx, England
[2] GlaxoSmithKline, Harlow, Essex, England
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] GlaxoSmithKline Res & Dev Ltd, Collegeville, PA USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4569
引用
收藏
页数：1
相关论文
共 50 条
[41]   Analysis of the UGT1A1 Genotype in Hyperbilirubinemia Patients: Differences in Allele Frequency and Distribution [J].
Mi, Xiao-xiao ;
Yan, Jian ;
Ma, Xiao-jie ;
Zhu, Ge-li ;
Gao, Yi-dan ;
Yang, Wen-jun ;
Kong, Xiao-wen ;
Chen, Gong-ying ;
Shi, Jun-ping ;
Gong, Ling .
BIOMED RESEARCH INTERNATIONAL, 2019, 2019
[42]   Do UGT1A1 and HMOX1 gene promoter polymorphisms increase the risk of hyperbilirubinemia and gallstones in patients with hereditary spherocytosis? [J].
Warang, Prashant ;
Devendra, Rati ;
D'Silva, Selma ;
Chiddarwar, Ashish ;
Kedar, Prabhakar ;
Ghosh, Kanjaksha ;
Colah, Roshan ;
Mukherjee, Malay B. .
ANNALS OF HEMATOLOGY, 2015, 94 (01) :169-171
[43]   Do UGT1A1 and HMOX1 gene promoter polymorphisms increase the risk of hyperbilirubinemia and gallstones in patients with hereditary spherocytosis? [J].
Prashant Warang ;
Rati Devendra ;
Selma D’Silva ;
Ashish Chiddarwar ;
Prabhakar Kedar ;
Kanjaksha Ghosh ;
Roshan Colah ;
Malay B. Mukherjee .
Annals of Hematology, 2015, 94 :169-171
[44]   The Effect of UGT1A1 Promoter Polymorphism in the Development of Hyperbilirubinemia and Cholelithiasis in Hemoglobinopathy Patients [J].
AlFadhli, Suad ;
Al-Jafer, Hassan ;
Hadi, Mays ;
Al-Mutairi, Mashael ;
Nizam, Rasheeba .
PLOS ONE, 2013, 8 (10)
[45]   Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms [J].
Deng Bo ;
Jia Liqun ;
Tan Huangying ;
Lou Yanni ;
Li Xue ;
Li Yuan ;
Yu Lili .
JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2017, 37 (01) :35-42
[46]   Linkage disequilibrium of UGT1A1*6 and UGT1A1*28 in relation to UGT1A6 and UGT1A7 polymorphisms [J].
Urawa, Naohito ;
Kobayashi, Yoshinao ;
Araki, Jun ;
Sugimoto, Ryosuke ;
Iwasa, Motoh ;
Kaito, Masahiko ;
Adachi, Yukihko .
ONCOLOGY REPORTS, 2006, 16 (04) :801-806
[47]   Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms [J].
Wenning, L. A. ;
Petry, A. S. ;
Kost, J. T. ;
Jin, B. ;
Breidinger, S. A. ;
DeLepeleire, I. ;
Carlini, E. J. ;
Young, S. ;
Rushmore, T. ;
Wagner, F. ;
Lunde, N. M. ;
Bieberdorf, F. ;
Greenberg, H. ;
Stone, J. A. ;
Wagner, J. A. ;
Iwamoto, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (06) :623-627
[48]   UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib [J].
Meza-Junco, Judith ;
Chu, Quincy S. -C. ;
Christensen, Olaf ;
Rajagopalan, Prabhu ;
Das, Soma ;
Stefanyschyn, Ruslan ;
Sawyer, Michael B. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) :1-4
[49]   Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population [J].
Chalirmporn Atasilp ;
Janjira Kanjanapipak ;
Jaratdao Vichayaprasertkul ;
Pimonpan Jinda ;
Rawiporn Tiyasirichokchai ;
Pornpen Srisawasdi ;
Chatchay Prempunpong ;
Monpat Chamnanphon ;
Apichaya Puangpetch ;
Natchaya Vanwong ;
Suwit Klongthalay ;
Thawinee Jantararoungtong ;
Chonlaphat Sukasem .
BMC Pediatrics, 22
[50]   The relationship between hyperbilirubinemia and the promoter region and first exon of UGT1A1 gene polymorphisms in Vietnamese newborns [J].
Nguyen, Tien-Thanh ;
Zhao, Wei ;
Yang, Xi ;
Zhong, Dan-Ni .
PEDIATRIC RESEARCH, 2020, 88 (06) :940-944
12345